Biren Amin
Stock Analyst at Piper Sandler
(3.53)
# 898
Out of 5,115 analysts
66
Total ratings
49.15%
Success rate
7.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Overweight | $7 | $2.31 | +203.03% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $24.18 | +98.51% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $20.34 | -21.34% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $77.27 | +26.83% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $15.82 | +323.51% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $9.14 | +239.17% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $60.38 | +57.34% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $3.51 | +70.94% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $2.61 | +53.26% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $6.46 | +163.16% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.84 | +280.43% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $24.57 | +54.66% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $6.40 | +87.50% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $29.04 | +144.49% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.27 | +323.22% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $24.62 | -14.70% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $68.31 | +68.35% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $22.58 | +41.72% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $2.84 | +5.63% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $2.43 | +2,780.66% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.27 | +18,859.11% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.36 | +347.76% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.51 | +653.88% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.53 | +94,239.62% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.55 | +46.60% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $741.45 | -6.80% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $5.69 | +75.75% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $47.41 | +113.04% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $136.06 | -49.29% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $469.90 | -67.01% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $4.06 | +3,249.75% | 4 | Mar 6, 2017 |
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $2.31
Upside: +203.03%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $24.18
Upside: +98.51%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $20.34
Upside: -21.34%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $77.27
Upside: +26.83%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $15.82
Upside: +323.51%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $9.14
Upside: +239.17%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $60.38
Upside: +57.34%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $3.51
Upside: +70.94%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $2.61
Upside: +53.26%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $6.46
Upside: +163.16%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.84
Upside: +280.43%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $24.57
Upside: +54.66%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $6.40
Upside: +87.50%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $29.04
Upside: +144.49%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.27
Upside: +323.22%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $24.62
Upside: -14.70%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $68.31
Upside: +68.35%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $22.58
Upside: +41.72%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $2.84
Upside: +5.63%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $2.43
Upside: +2,780.66%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.27
Upside: +18,859.11%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.36
Upside: +347.76%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $4.51
Upside: +653.88%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.53
Upside: +94,239.62%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.55
Upside: +46.60%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $741.45
Upside: -6.80%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $5.69
Upside: +75.75%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $47.41
Upside: +113.04%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $136.06
Upside: -49.29%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $469.90
Upside: -67.01%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $4.06
Upside: +3,249.75%